AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 203 filers reported holding AGIOS PHARMACEUTICALS INC in Q4 2019. The put-call ratio across all filers is 1.11 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $99,334,125 | -12.6% | 4,013,500 | 0.0% | 1.60% | -1.3% |
Q2 2023 | $113,662,320 | +23.3% | 4,013,500 | 0.0% | 1.62% | +21.2% |
Q1 2023 | $92,190,095 | -19.1% | 4,013,500 | -1.1% | 1.34% | -11.5% |
Q4 2022 | $113,914,719 | -0.8% | 4,056,792 | -0.0% | 1.51% | -8.2% |
Q3 2022 | $114,783,000 | +27.4% | 4,058,792 | -0.1% | 1.65% | +29.4% |
Q2 2022 | $90,072,000 | -25.1% | 4,062,792 | -1.6% | 1.27% | -8.8% |
Q1 2022 | $120,204,000 | -15.9% | 4,129,292 | -5.1% | 1.40% | -5.3% |
Q4 2021 | $142,961,000 | -28.7% | 4,349,292 | +0.2% | 1.47% | -27.5% |
Q3 2021 | $200,383,000 | -16.5% | 4,341,992 | -0.3% | 2.03% | -13.2% |
Q2 2021 | $239,893,000 | +2.4% | 4,352,992 | -4.1% | 2.34% | -5.5% |
Q1 2021 | $234,295,000 | +28.7% | 4,537,092 | +8.0% | 2.48% | +18.9% |
Q4 2020 | $182,029,000 | +25.3% | 4,201,002 | +1.2% | 2.08% | +3.9% |
Q3 2020 | $145,286,000 | -32.5% | 4,151,002 | +3.2% | 2.01% | -34.1% |
Q2 2020 | $215,181,000 | +55.3% | 4,023,573 | +3.0% | 3.04% | +13.3% |
Q1 2020 | $138,565,000 | -26.1% | 3,905,444 | -0.5% | 2.69% | -9.6% |
Q4 2019 | $187,417,000 | +62.0% | 3,924,954 | +9.9% | 2.97% | +38.1% |
Q3 2019 | $115,718,000 | -25.8% | 3,571,554 | +14.2% | 2.15% | -19.2% |
Q2 2019 | $156,031,000 | +10084.8% | 3,128,134 | +15650.1% | 2.66% | +2646.4% |
Q3 2018 | $1,532,000 | -36.9% | 19,861 | -31.1% | 0.10% | -53.1% |
Q2 2018 | $2,427,000 | -26.4% | 28,811 | -28.5% | 0.21% | -36.7% |
Q1 2018 | $3,296,000 | +41.0% | 40,300 | -1.5% | 0.33% | +34.0% |
Q4 2017 | $2,338,000 | -22.2% | 40,900 | -9.1% | 0.24% | -22.3% |
Q3 2017 | $3,004,000 | +29.8% | 45,000 | 0.0% | 0.31% | +14.6% |
Q2 2017 | $2,315,000 | -11.9% | 45,000 | 0.0% | 0.27% | -21.7% |
Q1 2017 | $2,628,000 | +39.9% | 45,000 | 0.0% | 0.35% | -9.1% |
Q4 2016 | $1,878,000 | -21.0% | 45,000 | 0.0% | 0.38% | -10.3% |
Q3 2016 | $2,377,000 | +57.6% | 45,000 | +25.0% | 0.43% | +51.1% |
Q2 2016 | $1,508,000 | -31.2% | 36,000 | -33.3% | 0.28% | -28.6% |
Q1 2016 | $2,192,000 | – | 54,000 | – | 0.40% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Rock Springs Capital Management LP | 2,661,605 | $61,137,067 | 1.46% |
Bellevue Group AG | 4,013,500 | $92,190,095 | 1.34% |
Eagle Health Investments LP | 267,630 | $6,147,461 | 1.20% |
ARMISTICE CAPITAL, LLC | 3,460,000 | $79,476,200 | 1.14% |
Integral Health Asset Management, LLC | 213,000 | $4,892,610 | 0.99% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 454,000 | $10,428,380 | 0.44% |
ArrowMark Colorado Holdings LLC | 1,557,705 | $35,780,484 | 0.41% |
FARALLON CAPITAL MANAGEMENT LLC | 2,092,829 | $48,072,282 | 0.27% |
Virtus ETF Advisers LLC | 9,932 | $228,138 | 0.13% |
JACOBS LEVY EQUITY MANAGEMENT, INC | 614,533 | $14,115,823 | 0.09% |